- Location
Watson Laboratories
"-
Initiation of Secure Supply Chain Pilot Program to Enhance The Security of Imported Drugs
Feb 19, 2014The U.S. Food and Drug Administration is announcing the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs. In August 2013, the FDA published a notice in the Federal Register (78 FR 51192) to ...
-
Horizon Pharma and SkyePharma Have Filed a Patent Infringement Lawsuit
Aug 30, 2013Horizon Pharma and SkyePharma have filed a patent infringement lawsuit against Watson Laboratories (WLF) and certain related companies like Actavis Pharma, Andrx and Actavis Inc. The lawsuit was filed in the US District Court for the ...
Tags: Horizon Pharma
-
Mylan Pharmaceuticals Has Introduced Norethindrone for The Prevention of Pregnancy in US
Jul 18, 2013Mylan Pharmaceuticals has introduced Norethindrone Tablets USP, 0.35mg, which is the generic version of Watson Laboratories' (now Actavis) Nor-Q.D. tablets, 0.35mg for 28-day cycle, for the prevention of pregnancy in the US. The ...
Tags: Generic Contraceptive Pill, Mylan
-
Watson Laboratories Received FDA Approval
Apr 11, 2013Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application for Vancomycin hydrochloride capsules, USP, 125mg and 250mg. The company has begun the shipment of the product ...
-
FDA Has Issued Marketing Approval for Oral Contraceptive Medication
Jan 24, 2013The US FDA has issued marketing approval for Lupin Pharmaceuticals' Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1mg / 0.02mg, the combined oral contraceptive. Levonorgestrel and Ethinyl Estradiol Tablets are the generic equivalent ...
Tags: FDA, Oral Contraceptive Medication, Lupin Pharmaceuticals
-
Depomed's Lawsuits Against Watson Laboratories and Par Pharmaceutical in Relation to ANDAs
Dec 31, 2012Depomed's lawsuits against Watson Laboratories and Par Pharmaceutical in relation to Abbreviated New Drug Applications (ANDAs) for Gralise (gabapentin) have been dismissed. The company said that both the companies no longer sought ...
Tags: Depomed, Watson Laboratories, Par Pharmaceutical, lawsuit
-
FDA Has Granted Regulatory Approval to Actavis's Diltiazem HCL Extended-Release Capsules
Dec 14, 2012The US Food and Drug Administration (FDA) has granted regulatory approval to Actavis' Diltiazem Hydrochloride (HCL) extended-release capsules. Actavis' Diltiazem HCL capsules are generic equivalent of Valeant's cardiovascular drug, ...
Tags: FDA, Actavis generic, cardiovascular drug
-
Watson Laboratories Won FDA Abbreviated New Drug Application Approval
Dec 5, 2012Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has won FDA abbreviated new drug application approval for Diclofenac Sodium and Misoprostol Delayed-Release Tablets. The company plans to launch Diclofenac Sodium and ...
Tags: Watson Laboratories
-
Watson Laboratories Gained FDA ANDA Approval for Next Choice ONE DOSE
Dec 5, 2012Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has gained FDA abbreviated new drug application (ANDA) approval for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5mg). The Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5mg) ...
Tags: ONE DOSE, levonorgestrel tablet, Watson Pharmaceuticals
-
Watson Laboratories Received FDA Approval for Its ANDA of Trospium Chloride Capsules
Dec 4, 2012Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application (ANDA) of Trospium Chloride Extended-release Capsules. Watson anticipates beginning the shipment of the ...
Tags: FDA, Trospium Chloride Extended-release Capsules, pharmaceutical product
-
Watson Anda for Budesonide Inhalation Suspension Be Approved by FDA
Nov 27, 2012Watson Laboratories,a subsidiary of Watson Pharmaceuticals,has won FDA approval for its abbreviated new drug application(ANDA)for Budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL unit-dose ampoules. Budesonide Inhalation ...
-
The USFDA Approved Watson Laboratories' ANDA for Lidocaine Topical Patch 5%
Aug 24, 2012The USFDA has approved Watson Laboratories' abbreviated new drug application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm. Lidocaine is an amide-type local anesthetic agent and is suggested to ...
-
Sunovion Lodged a Suit Against Watson for US Patents
Jun 15, 2012Watson Pharmaceuticals said Sunovion Pharmaceuticals has challenged Watson Laboratories filing of Abbreviated New Drug Application(ANDA)with the US Food and Drug Administration(FDA)seeking approval for marketing Levalbuterol Tartrate ...
Tags: Sunovion, FDA, Watson Laboratories
-
Auxilium Pharmaceuticals and FCB Filed a Patent Infringement Lawsuit
May 25, 2012Auxilium Pharmaceuticals and FCB have filed a patent infringement lawsuit, related to Testim 1% testosterone gel, against Watson Laboratories, Watson Pharmaceuticals, and Watson Pharma. The lawsuit was filed in the US District Court ...
Tags: patent infringement lawsuit, Watson, generic product, FDA
-
Watson Pharmaceuticals Confirmed The Filing of ANDA with FDA
May 21, 2012Watson Pharmaceuticals has confirmed the filing of ANDA with FDA by Watson Laboratories seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets, 1mg/0.01mg and 0.01mg and 75mg. ...
Tags: pharmaceutical product, pregnancy prevention drug, FDA
Related Products
-
Factory Direct Sale Wholesale Price Laboratory 5ml Short Filter Tip with Wide Mouth Rack Package for Satorius Dragon Watson Gilson P Series Pipettor
-
Chemistry Laboratory Equipment Experimental 5ml Short Filter Tip with Wide Mouth Bag Package for Satorius Dragon Watson Gilson P Series Pipettor
-
Laboratory Pipette Medical Supply 5ml Short Tip with Wide Mouth Rack Package for Satorius Dragon Watson Gilson P Series Pipettor
